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Abstract
Monoclonal antibodies (mAbs) can be potent and highly specific therapeutics, diagnostics and research reagents.
Nonetheless, mAb discovery using current in vivo or in vitro approaches can be costly and time-consuming, with no
guarantee of success. We have established a platform for rapid discovery and optimization of mAbs ex vivo. This DTLacO
platform derives from a chicken B cell line that has been engineered to enable rapid selection and seamless maturation of
high affinity mAbs. We have validated the DTLacO platform by generation of high affinity and specific mAbs to five cell
surface targets, the receptor tyrosine kinases VEGFR2 and TIE2, the glycoprotein TROP2, the small TNF receptor family
member FN14, and the G protein-coupled receptor FZD10. mAb discovery is rapid and humanization is straightforward,
establishing the utility of the DTLacO platform for identification of mAbs for therapeutic and other applications.
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Introduction
Monoclonal antibodies (mAbs) are well-established as therapeu-
tics, diagnostics, and reagents for research, but their use is currently
limited by the difficulties and costs associated with identifying mAbs
withtherequired affinityand specificity.Manytargetsofinterestare
highly conserved proteins, and immune regulation limits antibodies
that can be obtained from a physiological immune response. In
addition, many key therapeutic targets are cell surface proteins,
which present particular challenges to mAb development because
their physiologically active conformations are not readily recapit-
ulated by purified proteins or membrane preparations used for
immunization to elicit specific antibodies. This includes some
especially high value targets, such as cytokine receptors and G
protein-coupled receptors.
Most current strategies for mAb discovery depend on in vivo and
in vitro approaches. In vivo approaches depend on activation and
selection of specific B cells by immunization, followed by
generation of hybridomas [1,2]. This process is costly and time-
consuming, since extensive screening and, in many cases,
subsequent steps including affinity maturation are required to
obtain mAbs with desired properties. It is also limited by immune
tolerance, making some antigens difficult or impossible to target.
In addition, once a mAb has been identified there is not a
straightforward path to further optimization of affinity or
functionality. In vitro approaches rely on screening massive
numbers of synthetic single-chain antibodies, typically displayed
on phage [3,4]. These antibodies are expressed by cloned genes
that encode linked VH and VL regions derived from an immune
repertoire, often from a convalescent individual [5,6]. They can be
further optimized by iterative PCR-based mutagenesis accompa-
nied by selection in vitro, using high throughput approaches.
However, success in the end depends on the quality of the starting
libraries and their sources, and not all single-chain antibodies can
be readily converted to natural antibodies for practical applica-
tions.
mAb discovery can also be carried out ex vivo in immortalized B
cells. B cells display immunoglobulin (Ig) molecules on the cell
surface, facilitating selection for antigen recognition. In some B cell
lines, physiological pathways for Ig gene diversification remain
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36032active, enabling evolution of high affinity antibodies in culture.
The chicken B cell line, DT40, has proven especially adaptable for
such purposes [7,8,9]. DT40 derives from a bursal lymphoma, and
cells constitutively diversify their VH and VL genes [10]. Ongoing
diversification occurs by two pathways [11]. Most mutations are
templated and arise as a result of gene conversion, with
nonfunctional pseudo-V regions serving as donors for transfer of
sequence to the rearranged and transcribed V gene. A small
fraction of mutations are nontemplated, and arise as a result of
somatic hypermutation, the mutagenic pathway that generates
point mutations in Ig genes of antigen-activated human and
murine B cells. DT40 cells proliferate rapidly, with an 8–10 hr
doubling time (compared to 20–24 hr for human B cell lines), and
are robust to experimental manipulations including magnetic-
activated cell sorting (MACS), fluorescence-activated cell sorting
(FACS) and single-cell cloning. Most importantly, DT40 cells
support very efficient homologous gene targeting [12], so genomic
regions can be replaced or modified at will.
Despite the considerable potential of DT40 cells for antibody
evolution, their utility has thus far been limited in practice because
— as in other transformed B cell lines — Ig gene diversification
occurs at less than 1% the physiological rate. Several approaches
have been used to accelerate diversification in DT40 cells.
Disabling the homologous recombination pathway accelerates
point mutagenesis, but cells thus engineered have lost the ability to
diversify their Ig genes by gene conversion or to carry out gene
targeting; and all mutations are nontemplated point mutations,
like those generated during antigen-driven somatic hypermutation
in humans or mice [7]. Treatment of cells with the histone
deacetylase inhibitor, trichostatin A accelerates gene conversion
[8], but does not promote point mutagenesis, limiting potential
diversity. By transfecting DT40 cells with inducible transgenes
expressing factors necessary for homologous repair, it is possible to
toggle between diversification that generates templated or
nontemplated mutations [9], but this does not significantly affect
the rate of diversification.
We have now engineered DT40 cells to accelerate the rate of Ig
gene diversification, without sacrificing the capacity for further
genetic modification or the potential for both gene conversion and
somatic hypermutation to contribute to V region mutagenesis.
Distinct steps of engineering were carried out to generate the
DTLacO platform, which enables rapid and seamless selection of
high affinity mAbs ex vivo under control of the potent LacO/LacI
regulatory network. We have demonstrated generation of high
affinity mAbs against six targets, including the model antigen,
streptavidin (SAv), and five cell surface antigens, the receptor
tyrosine kinases VEGFR2 and TIE2, the glycoprotein TROP2,
the TNF receptor family member FN14, and the G protein-
coupled receptor FZD10. These results establish the power of the
DTLacO platform for identification of mAbs for therapeutic and
other applications.
Results
The DTLacO mAb discovery platform
The DTLacO platform for rapid mAb selection and optimiza-
tion was developed by engineering DT40 cells to put diversifica-
tion under control of the powerful E. coli LacO/LacI regulatory
network. Regulation by LacO/LacI takes advantage of the high-
affinity (kD=10
214 M) of lactose repressor (LacI) for lactose
operator (LacO), as well as the sensitivity of the LacI/LacO
interaction to the small molecule, IPTG. We initially generated a
cell line, DT40 PolyLacO-lR, in which polymerized lactose
operator (‘‘PolyLacO’’) had been upstream of the rearranged and
expressed immunoglobulin l light chain gene (IglR) by homol-
ogous gene targeting [13]. We showed that, in this line, the rate
and outcome of diversification could be controlled by expression of
distinct regulatory factors fused to LacI [13,14,15].
We then further modified these cells in two steps (Figure 1), both
of which took advantage of the high efficiency of gene targeting in
the parental chicken DT40 B cell line. First, we inserted the potent
PolyLacO regulatory element upstream of the rearranged and
expressed IgH gene in the DT40 PolyLacO-lR cell line, which
carries PolyLacO at Igl [13]. This created the DTLacO-1
population, which carries PolyLacO at both Igl and IgH,
upstream of the endogenous rearranged VH (VDJ) and Vl (VJ)
regions. Next, we substituted a VH library generated from chicken
bursal B cells for the single endogenous VH region. This expanded
the initial VH repertoire, and created the DTLacO-2 population.
Synergistic acceleration of diversification by PolyLacO
targeted to both Igl and IgH
The presence of PolyLacO at both Igl and IgH should
accelerate diversification. We tested this by comparing diversifi-
cation rates in DTLacO-1 cells, engineered to carry PolyLacO
targeted to both the Igl and the IgH genes, relative to DT40
PolyLacO-lR cells, which carry PolyLacO only at Igl. Diversi-
fication rates of candidate engineered lines were determined by
assaying the fraction of sIgM
2 cells 3 weeks post-transfection with
the LacI-HP1 regulatory factor. Representative candidates exhib-
ited diversification rates of 6.9%, 12.6% and 25.7% (e.g. Fig. 2A),
from 2.5- to 9.2-fold elevated relative to the 2.8% characteristic of
the parental DT40 PolyLacO-lR LacI-HP1 line. Accelerated
diversification was reconfirmed for one line by fluctuation assay of
individual transfectants (Fig. 2B). Percentages of sIgM
2 cells
ranged from 2.5% to 52.5%, with a median of 13.0% (Fig. 2B),
4.6-fold higher than in DT40 PolyLacO-lR LacI-HP1 transfec-
tants (2.8%), and 21.7-fold higher than in control DT40
PolyLacO-lR GFP-LacI cells (0.6%, comparable to the DT40
parental line [13]). Some individual clones exhibited sIgM loss
considerably different than the median, as predicted because this
fluctuation assay measures accumulated sIgM
2 variants. Thus,
targeting PolyLacO elements to both the heavy and light chain
genes accelerated diversification nearly 22-fold relative to the
DT40 parental cell line (Fig. 2C). Diversification was also
accelerated upon transfection of these cells with other regulatory
factors expressed as LacI fusions, including GFP-LacI-VP16 and
E47-LacI (not shown).
Ex vivo evolution of anti-streptavidin antibodies
To test the utility of DTLacO cells for ex vivo mAb evolution, we
selected mAbs against the model antigen, streptavidin (SAv) [7,8]
from the DTLacO-1 population (Figure 1, Step 1). Cells were
stably transfected with an E47-LacI expression construct, which
encodes a fusion of LacI and the E47 isoform of the regulatory
factor, E2A. E47 is a transcriptional regulator in some contexts,
but at the Ig genes of DT40 cells it promotes diversification but not
transcription [15]. A diversified population of 3610
8 DTLacO
E47-LacI cells was enriched twice for binding to SAv-conjugated
magnetic beads, then selected by successive rounds of FACS for
binding to SAv-PE. The cell population exhibited increased
affinity after each round of selection. A 30-fold shift was evident
after the fifth round of selection and a 100-fold shift by the seventh
round (S5 and S7, respectively; Figure 3A). The binding affinity of
the S7 population for SAv-PE-Cy7 was measured by saturation
binding kinetics. In this FACS-based method, cells are stained with
increasing concentrations of antigen until equilibrium of bound
and unbound antigen is established; the resulting mean fluores-
Accelerated Ex Vivo Antibody Discovery
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(GraphPad); and the affinity at equilibrium (kD) is determined
(Figure 3B). The apparent affinity was found to be 0.7 nM, after 7
rounds of selection, which compares favorably with 15–19 rounds
of selection required for selection of antibodies of comparable
affinity ex vivo using cultured human B cell lines [7]. The sequences
of the VH and Vl regions were determined by PCR amplification
from single cells, and compared to the germline [16,17]. Strikingly,
an 18 residue insertion/duplication was identified in CDR1 of Vl
(Figure 3C). An insertion in light chain CDR1 of anti-SAv mAbs
has also been reported by others using DT40 cells that have not
undergone any genetic engineering [8].
Selection of high affinity mAbs that recognize conserved
cell surface receptors
The DTLacO-1 cells stably expressing LacI-HP1 were selected
to identify mAbs against three cell surface antigens of therapeutic
interest: the receptor tyrosine kinases, VEGFR2 and TIE2, which
play essential roles in physiologic and pathologic angiogenesis,
most notably in cancer [18,19]; and the glycoprotein, TROP2,
which is overexpressed in numerous epithelial cancers [20]. The
extracellular domains of these receptors are highly conserved, with
the human and murine orthologs exhibiting 80%, 90%, and 83%
identity, respectively. Each extracellular domain was expressed as
recombinant protein fused to the human IgG1 Fc domain.
DTLacO cells specific for each antigen were enriched from 1610
9
cells by initial selection on the antigen bound to magnetic beads
and then for binding to the soluble antigen by FACS. Eight
successive selected populations were characterized and shown to
exhibit increased affinity at each selection step (Figure 4A, above).
At the eighth selection step, analysis of saturation binding kinetics
of the soluble antigens to their cognate DTLacO populations
established apparent affinity values (kD) of 6.0, 1.4, and 2.0 nM,
respectively (Figure 4A, below). Specificity of individual selected
populations was tested by assaying binding to a panel of antigens
(VEGFR2, TIE2, TROP2, SAv and ovalbumin). The selected
DTLacO cells recognized only the cognate target, and were not
cross-reactive (Figure 4B).
CDR-targeted mutations characterize high affinity mAbs
Recombinant, chimeric chicken-human mAbs were generated
by cloning the VH and Vl regions from the DTLacO cells that
recognized VEGFR2, TIE2 or TROP2 into a construct for
expression fused to human c1 heavy- and l light-chain constant
regions. The chimeric mAbs preserved high affinity antigen
recognition (data not shown), showing that the B cell receptor
conferred high affinity binding by the selected cells. Sequence
analysis of the cloned VH and Vl regions showed that mutations
conferring high affinity and specificity mapped primarily to CDRs
(Figure 4C). Both templated and nontemplated mutations were
evident in the CDRs, although not all mutations in the heavy
chain could be definitively assigned to a pathway, as the entire
array of yVH segments has not yet been sequenced.
Expanded VH diversity further accelerates mAb selection
DTLacO cells expressing regulatory LacI-fusion factors, from
either the initial population or the population in which the
repertoire had been expanded by VH replacement (DTLacO-1
and DTLacO-2, respectively; Figure 1), were the sources of mAbs
recognizing two other antigens of therapeutic interest, the small
TNF receptor family member, FN14 [21], and the G protein-
coupled receptor, FZD10 [22]. Both proteins have highly
conserved extracellular domains (92% and 94% identity, respec-
tively, between human and mouse). An anti-FN14 mAb (FS24;
Leppard et al., manuscript in preparation) was selected from the
DTLacO-1 population and matured by LacI-HP1-driven diver-
sification (Figure 5A). Subnanomolar affinity (kD=0.44 nM) was
achieved after 17 rounds of selection over 12 weeks, and affinity
improved only modestly in the course of 7 additional selections
over the next 4 weeks (kD=0.26 nM). An anti-FZD10 mAb (FZ2;
Cummings et al., manuscript in preparation) was selected from the
DTLacO-2 population, with diversification accelerated by the
tethered factor HIRA-GFP-LacI [14]. The population reached
subnanomolar affinity after only four rounds of selection, over 8
weeks (Figure 5A). This mAb recognized its target with apparent
affinity kD=0.16 nM. Sequence analysis of the cloned VH and Vl
regions showed that mutations conferring high affinity and
specificity mapped primarily to CDRs (Figure 5B; note that
sequence analysis does not distinguish mutations in the mAb FZ2
VH region that occurred as a result of VH region swap and LacO/
LacI-driven diversification.).
Facile humanization of chicken antibodies
Antibodies selected in mice or other species are typically
humanized for therapeutic applications [23]. The anti-FN14 and
anti-FZD10 mAbs were chosen for humanization, as their high
affinity and distinct heavy-chain CDRs offered a robust test of this
key step in mAb development. Chicken VH and Vl regions are
most closely related to human VH subgroup III and Vl subgroup
III, respectively. These are well-established frameworks for
humanization, and have been used previously to humanize mAbs
elicited by immunization of chickens [24,25]. The structure of a
Figure 1. Two steps of engineering accelerate clonal diversification. Schematic diagram of the rearranged and expressed IgH locus, showing
the variable (VDJ) region, the constant (Cm) region, and the upstream yVH array. IgH was first modified by insertion of PolyLacO within the yVH array
in DT40 PolyLacO-lR cells, which carry PolyLacO targeted to the rearranged and expressed Igl locus [13,14,15]. Next, this locus was further modified
by substitution of the endogenous VH (VDJ) region with VH regions from a naive chick.
doi:10.1371/journal.pone.0036032.g001
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itself but also by a small number of nearby ‘‘Vernier zone’’
residues that contribute to shaping CDR structure [26]. Scaffolds
for CDR grafting were generated by modifying human framework
regions at the few positions necessary to achieve identity with the
Vernier zone residues of the corresponding chicken VH or Vl
region. The framework scaffolds thereby generated are 94–96%
identical to human, making immunogenicity very unlikely. The
first two N-terminal residues of light chains were also eliminated,
as these residues lie proximal to CDR1 in mammalian antibodies
and could in principle interfere with interaction with antigens. The
CDRs of the chicken mAbs were then grafted to the modified
scaffolds, to create the humanized VH and Vl regions (Figure 5C).
Comparisons of apparent binding affinities of the humanized anti-
FN14 and anti-FZD10 mAbs showed that humanization was
achieved without loss of affinity (Figure 5D). This facile
humanization contrasts to murine antibodies, which require
considerable empirical optimization.
Discussion
The DTLacO platform permits rapid ex vivo discovery of mAbs
that recognize highly conserved targets. We have demonstrated
the power of the DTLacO platform by generating specific and
high affinity mAbs to five cell surface antigens of therapeutic
interest, the receptor tyrosine kinases VEGFR2 and TIE2, the
glycoprotein TROP2, the small TNF receptor family member
FN14, and the G protein-coupled receptor FZD10. The highly
conserved extracellular domains of these cell surface receptors are
likely to make them difficult targets for in vivo mAb discovery,
which is limited by immune tolerance. Time from initial selection
to identification of a high-affinity mAb (,10 nM) was on the order
of 4–8 weeks, and subnanomolar affinity was achieved in 8–12
weeks. This compares very favorably with other ex vivo or in vivo
platforms for mAb discovery.
The DTLacO ex vivo mAb discovery platform provides several
additional advantages relative to other mAb discovery approaches.
The cells produce intact antibodies, which can immediately be
tested for desired properties, whereas many in vitro approaches like
phage-display system produce single-chain antibodies, which are
frequently difficult to convert to active full-length mAbs due to
aggregation or instability. The DTLacO cells diversify V regions
using physiological pathways (somatic hypermutation and gene
conversion), which target mutations mainly to CDRs, the
subdomains of V regions that directly contact antigens. Further-
more, the cells proliferate rapidly and they are immortal, so at
each step of selection the cell population provides not only a
renewable source of antibodies (or VH and VL sequences for
expression of recombinant antibodies), but also a starting point for
further optimization.
The DTLacO platform is distinguished from other mAb
discovery platforms based on DT40 cells [7,8] by the ability to
access both physiological diversification pathways, somatic hyper-
mutation and gene conversion. DTLacO cells also retain the
ability to carry out homologous gene targeting, which permits
additional genetic engineering. We took advantage of this by
substituting the endogenous VH region with a VH library, to create
the DTLacO-2 population carrying an expanded VH repertoire.
The third heavy chain CDR, CDR-H3, includes the VDJ junction
and is a major determinant for antigen recognition [27]. CDR-H3
diversity may have contributed to the rapid selection of a high
affinity anti-FZD10 mAb from the DTLacO-2 population. It is
also possible to swap human for chicken V regions (data not
shown), which will permit optimizing affinity or functionality of
mAbs discovered by other methods, as well as direct discovery of
human therapeutic mAbs.
The chicken mAbs optimized in DTLacO cells proved to be
readily humanized by CDR grafting into consensus human VH
subgroup III and Vl subgroup III framework regions in which
Vernier zone residues had been modified to preserve CDR
structure. Humanization was carried out without loss of affinity,
and achieved .94% identity to human within the framework
regions. This is comparable to or better than many humanized
murine mAbs now in the clinic, and makes immunogenicity very
Figure 2. Clonal diversification rate accelerated in DTLacO
cells. (A) sIgM loss assay of three representative clonal DTLacO LacI-
HP1 transfectants. Fraction of sIgM
2 cells in each culture indicated at
lower right in each panel. (B) Summary of sIgM loss assays. Each open
circle represents the percentage of sIgM
2 cells in one clonal
transfectant, analyzed 3 weeks post-transfection. Cells analyzed were:
DT40 PolyLacO-lR GFP-LacI control transfectants (n=27); DT40 Poly-
LacO-lR LacI-HP1 transfectants (n=16) and DTLacO LacI-HP1 transfec-
tants (n=20). (C) Median sIgM loss of DT40 PolyLacO-lR LacI-HP1 and
DTLacO LacI-HP1 transfectants relative to GFP-LacI control transfec-
tants.
doi:10.1371/journal.pone.0036032.g002
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contrasts to antibodies discovered in mice or murine cells, which
must undergo empirical optimization. VH subgroup III and Vl
subgroup III framework regions are conserved among a number of
vertebrates, raising the possibility that mAb frameworks could be
modified for treatment of chronic illness in other species.
The rapid selection and humanization we have documented
establish the utility of the DTLacO platform for therapeutic mAb
discovery. Operationally, the platform is readily adaptable to high
throughput approaches. This will facilitate application of the
platform to discovery of mAbs for diagnostic and research
applications, and make the platform especially well-suited for
development of mAbs for personalized medicine.
Figure 3. Rapid evolution of anti-SAv antibodies in DTLacO cells. (A) SAv binding profile of successive selected cell populations of DTLacO
(left) or DTLacO E47-LacI (right) cells. Selection was carried out on average weekly. Cell numbers plotted relative to SAv-PE fluorescent signal.
Populations at successive rounds of selection designated above peaks (S0–S7). Pre, populations prior to any sorting (gray fill). (B) Saturation binding
kinetics of DTLacO E47-LacI S7 population. (C) Sequences of high affinity selected anti-SAv mAb compared to the germline [16,17]. CDRs are
identified by background shading. The D6 sequence was chosen as the germline D element for comparison [17]. Note the 18-residue insertion/
duplication in CDR1 of Vl of the anti-SAv mAb, recapitulating an insertion in light-chain CDR1 reported by others selecting anti-SAv mAbs from DT40
cells that had not undergone any genetic engineering [8].
doi:10.1371/journal.pone.0036032.g003
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Cell culture and gene targeting
DT40-derived cell lines ([13,14,15] and in this study) were
maintained and transfected as previously described [28]. FreeStyle
293-F cells (Invitrogen) were maintained and transfected as
specified by the manufacturer.
PolyLacO was targeted to the yVH array using the targeting
construct, pPolyLacO-yVH, designed to promote homologous
recombination at the rearranged and expressed heavy chain allele
of DT40 PolyLacO-lR cells. These cells had been previously
Figure 4. High affinity mAbs selected from DTLacO cells. (A) Above, binding profiles of successive DTLacO LacI-HP1 populations selected for
recognition of cell surface receptors, VEGFR2, TIE2 and TROP2. Rounds of selection designated above peaks (S0–S8). Below, saturation binding
kinetics, indicating apparent kD. (B) Specificity of selected DTLacO populations. FACS analysis of binding of cell populations selected for high affinity
recognition of VEGFR2, TIE2 or TROP2 to recombinant VEGFR2, TIE2, TROP2, SAv or ovalbumin (OVA). Solid peaks represent the negative reference
control (secondary antibody alone), and green lines represent staining with antigen. (C) Schematic alignment of VH and Vl regions of mAbs selected
for binding to VEGFR2, TIE2 and TROP2. Thin horizontal blue lines represent chicken framework regions, thicker horizontal lavender lines against
background shading identify CDRs, vertical bars indicate single residue differences relative to the most common DTLacO sequence, and triangle
indicates insertion.
doi:10.1371/journal.pone.0036032.g004
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light chain allele [13,14,15]. To generate the pPolyLacO-yVH
targeting construct, 2.8- and 4.2-kb homology arms were obtained
from yVH array fragments amplified from DT40 genomic DNA
using primers 59-GGGGTCTCTATGGGGTC-
TAAGCGTGGCC-39 and 59-GGCCGATTCTTTTCTCAT-
GAGATCCCTCCAGAAG-39or59-TTCCCCACAACCAGGC-
CATGCGCCTCCTTG-39 and 59-
CCTGCAGACACCCAGAGGAGGGCTCAGC-39. These two
homology arms were subcloned into pBluescript II KS(+) (Strata-
gene), adjacent to a blasticidin-resistance gene to enable selection of
stable transfectants following about 10 days growth in 20 mg/ml
concentration of blasticidin (Invitrogen). The PolyLacO regulatory
element [29], which consists of approximately 100 repeats of a 20-
merlactoseoperator(LacO),andwasakindgiftofA.S.Belmont(U.
Illinois, Urbana), was cloned between the homology arms. The
constructwasverifiedbyrestrictionanalysesandpartialsequencing,
and propagated in recombination-deficient E. coli strains Stbl2
(Invitrogen) to maintain repeat stability. Targeting was carried out
essentially as previously described [15]. DT40 PolyLacO-lR cells
weretransfected,andstabletransfectantswerescreenedbygenomic
PCR and Southern blotting to identify homologous integrants.
The VH (VDJ) region repertoire of DTLacO cells was expanded
in two steps of gene targeting, both of which relied on the targeting
vector,pVDJ3.TogeneratepVDJ3,2.2-and1.8-kbhomologyarms
were amplified from DT40 genomic DNA using primers 59-
TGAATGCTTTGTTAGCCCTAATTAGGGATTGAATTGA-
GAG-39 and 59-CCGTGAGACCCCCCGTTGACC-39 or 59-
GCCCGACCGAAGTCATCGTCTCCTCCGGTG-39 and 59-
TTTGCCTTCAAATCACCCTA-39, respectively, and fused to
the leader-VDJ region and cloned into pBluescript II KS(+). The
pVDJ3-GFP targeting construct derivative was generated by
Figure 5. Selection and humanization of anti-FN14 and anti-FZD10 mAbs. (A) Schematic of time course of selection of anti-FN14 and anti-
FZD10 mAbs, with selection steps indicated by S, and apparent affinities (kD) of recombinant chimeric mAbs shown below. (B) Schematic alignment
of VH and Vl regions of mAbs selected for binding to FN14 and FZD10. Thin horizontal lines represent chicken framework regions, thicker horizontal
lines against background shading identify CDRs, vertical bars indicate single residue differences relative to the most common DTLacO sequence, and
triangle indicates insertion. (C) Antibody humanization. VH and Vl regions of humanized mAbs hFS24 and hFZ2 schematically aligned to the human
VH-III or Vl-III consensus (top lines). Thin horizontal lines represent human framework regions; asterisks denote the two residues eliminated from the
N-terminal of the light chain; vertical lines outside background shading identify Vernier zone residues preserved in humanized mAbs; other notations
as in Panel B. (D) Apparent affinities (kD) of humanized and progenitor mAbs.
doi:10.1371/journal.pone.0036032.g005
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[30]. The pVDJ3-Bin1 targeting construct pool was generated by
insertingalibraryofVHregionsintotheXcmI-PshAIsiteofpVDJ3.
Those sequences had been amplified from the bursa of a 2 month-
old White Leghorn chick using PCR primers 59-
GGGTCTGCGGGCTCTATGGGG-39 and 59-
ATCGCCGCGGCAATTTTGGGG-39. Expansion of the reper-
toire was accomplished by first replacing the endogenous VDJ
region in DTLacO cells with a GFP expression cassette using
pVDJ3-GFP; and next replacing GFP with the pVDJ3-Bin1
targeting construct pool, producing sIgM
+ cells.
Transfections for heavy chain targeting were carried out using a
Nucleofector (program B-023; Lonza). sIgM
+ cells were collected
by MACS and then FACS. Briefly, following 2 days posttransfec-
tion, cells were washed in PBS containing 1% BSA (Sigma), and
sIgM
+ cells enriched by binding to protein G Dynabeads (Dynal)
coupled to anti-chicken IgM (Southern Biotech) according to
manufacturers’ directions. After two days culture, sIgM
+/GFP
2
cells were sorted using a FACSAria (BD Biosciences), generating
the DTLacO-2 population.
Quantitation of diversification rates
Diversification rates were quantified using the sIgM loss assay,
which measures the fraction of cells that have lost expression of
IgM on the cell surface due to diversification events [28,31,32]. In
brief, panels of approximately 20 independent transfectants were
expanded for 3 weeks, then cells (,1610
6) from each panel
member were stained with R-PE conjugated anti-chicken IgM
(1:200; Southern Biotech), and analyzed on a FACScan with
CellQuest software (BD Biosciences). Cells with fluorescence
intensity less than one-eighth the median of the sIgM
+ peak were
scored as sIgM
2 [31,33].
V region sequence analysis
V-region PCR and sequence analysis were performed essentially
as described [13,28], using primers 59-CAG-
GAGCTCGCGGGGCCGTCACTGATTGCCG-39 and 59-
GCGCAAGCTTCCCCAGCCTGCCGCCAAGTCCAAG-39
for amplification of the rearranged Vl regions and primers 59-
GGGTCTGCGGGCTCTATGGGG-39 and 59-
ATCGCCGCGGCAATTTTGGGG-39 for amplification of the
rearranged VH regions When necessary, semi-nested PCR was
carried out using a second-round primer 59-TCACT-
GATTGCCGTTTTCTCCCCTCTCTCC-39 for the Vl regions
or 59-GGTCAACGGGGGGTCTCACGG-39 for the VH regions.
PCR products were purified with QIAquick PCR purification kit
(Qiagen) and sequenced directly.
Antigens and selection for antigen binding
Initial selections were performed by binding diversified
DTLacO populations to magnetic beads complexed with antigens,
and subsequent selections by FACS using fluorescence-labeled
soluble antigens, following procedures previously described [7,8]
with minor modifications. In some cases, pre-clearing of non-
specific DTLacO cells was carried out using unbound beads to
efficiently enrich positive populations. SAv Dynabeads M-280
(Dynal) and SAv-PE (Southern Biotech) were used to select cells
that recognized SAv. Selection of cells that recognized human cell
surface proteins used recombinant human chimeric proteins,
expressed as fusions with human IgG1 Fc (R&D Systems),
including the extracellular domain of VEGFR2 (residues 20–
764; Cat. no. 357-KD), TIE2 (residues 23–745; Cat. no. 313-TI),
TROP2 (residues 88–274; Cat. no. 650-T2), FN14 (residues 28–
79; Cat. no. 1199-TW) or FZD10 (residues 21–161; Cat.
no. 3459-FZ). Chimeric proteins were bound to protein G
Dynabeads (Dynal) using manufacturers’ recommended condi-
tions for MACS method, and detected with PE-Cy5-labeled anti-
human IgG Fc (Southern Biotech; 1:200) for FACS method.
Antigens for selection were used at concentrations of 10 mg/ml;
selections were carried out on .10
8 cells at a bead:cell ratio
ranging from 3:1 to 1:1.
Binding and affinity assays
Saturation binding kinetics were determined by staining cells
with various concentrations of fluorescent-labeled soluble antigens,
and apparent affinities (kD) were calculated by nonlinear regression
using GraphPad Prism software. To test binding of mAbs to the
cell surface antigens, recombinant chimeric chicken-human mAbs
were generated by cloning PCR-amplified VH and Vl segments in
frame into pcDNA3.1 (Invitrogen) derivatives, pcDNA3.HG1 and
pcDNA3.HLam, carrying the human c1 and l constant regions,
respectively. The expression plasmids were cotransfected tran-
siently into FreeStyle 293-F cells (Invitrogen) according to the
manufacturer’s instruction. After 2–4 days culture, secreted
antibodies were purified from supernatants by protein A
chromatography (MabSelect SuRe; GE Healthcare) and, if
necessary, concentrated by Ultracel ultrafiltration (Millipore).
Target cells were generated by transient transfection of 293-F
cells with antigen expression constructs (GeneCopoeia).
Antibody humanization
To humanize the chicken mAbs, CDRs of anti-FN14 and anti-
FZD10 mAbs were grafted into human frameworks VH subgroup
III and Vl subgroup III [23]. Vernier zone residues [26] were
modified by Quikchange site-directed mutagenesis (Agilent Tech-
nologies). The humanized VH and Vl regions were then
transferred into pcDNA3.1-derived human IgG1 or Igl expression
constructs, and mAbs were expressed and purified using protein A
as above.
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